Eiger BioPharmaceuticals, Inc.

ACTIVE

2155 Park Blvd, 加利福尼亚州圣马特奥县, California, United Stateswww.eigerbio.comPublic25 employeesEstablished: 2008-01-01

Also known as:

EIGR

Eiger

Clinical Trials

12 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

2008

Overview

Trial Phase Distribution

Phase

Trials

Phase 1

100.0%

Trial Status Distribution

Active, not recruiting

100.0%

Clinical Trials

Trials sponsored by this organization (12)

A Phase 3, Randomized, Open-Label, Parallel Arm Study to Evaluate the Efficacy and Safety of 180 mcg Peginterferon Lambda-1a (Lambda) Subcutaneous Injection for 48 Weeks in Patients with Chronic Hepatitis Delta Virus (HDV) Infectio

Phase 1

Active, not recruiting

interventional

Mar 2022150 participants

A research study to evaluate the efficacy and safety of the study drug named Lonafarnib administrated with Ritonavir, in patients Chronically Infected with Hepatitis Delta Virus Being Maintained on Anti-HBV Nucleos(t)ide Therapy (D-LIVR)

Phase 1

Active, not recruiting

Mar 2022400 participants

A Phase 3, Randomized, Open-Label, Parallel Arm Study to Evaluate the Efficacy and Safety of 180 mcg Peginterferon Lambda-1a (Lambda) Subcutaneous Injection for 48 Weeks in Patients with Chronic Hepatitis Delta Virus (HDV) Infectio

Phase 1

Active, not recruiting

Nov 2021150 participants

A Phase 3, Randomized, Open-Label, Parallel Arm Study to Evaluate the Efficacy and Safety of 180 mcg Peginterferon Lambda-1a (Lambda) Subcutaneous Injection for 48 Weeks in Patients with Chronic Hepatitis Delta Virus (HDV) Infectio

Phase 1

Active, not recruiting

Nov 2021150 participants

A research study to evaluate the efficacy and safety of the study drug named Lonafarnib administrated with Ritonavir, in patients Chronically Infected with Hepatitis Delta Virus Being Maintained on Anti-HBV Nucleos(t)ide Therapy (D-LIVR)

Phase 1

Active, not recruiting

Aug 2021400 participants

A research study to evaluate the efficacy and safety of the study drug named Lonafarnib administrated with Ritonavir, in patients Chronically Infected with Hepatitis Delta Virus Being Maintained on Anti-HBV Nucleos(t)ide Therapy (D-LIVR)

Phase 1

Active, not recruiting

May 2019400 participants

A research study to evaluate the efficacy and safety of the study drug named Lonafarnib administrated with Ritonavir, in patients Chronically Infected with Hepatitis Delta Virus Being Maintained on Anti-HBV Nucleos(t)ide Therapy (D-LIVR)

Phase 1

Active, not recruiting

Apr 2019400 participants

A research study to evaluate the efficacy and safety of the study drug named Lonafarnib administrated with Ritonavir, in patients Chronically Infected with Hepatitis Delta Virus Being Maintained on Anti-HBV Nucleos(t)ide Therapy (D-LIVR)

Phase 1

Active, not recruiting

Apr 2019400 participants

Page 1 of 2

Approvals

Approvals by Agency

FDA

Food and Drug Administration

Approvals

Recent Approvals

Zokinvy

FDA

2024-04-04

News

No news articles found

Back to Organizations